Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking approach to diabetes management. These innovative drugs operate by mimicking the inherent actions of GLP-1, a hormone released by the gut in response to consumption. By stimulating GLP-1 receptors in the pancreas, these agents enhance insulin release and reduce glucag

The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing contrasts in t